ABSTRACT:
RP-HPLC method until now no analytical method by RP-HPLC was reported for its determination in bulk drug and in pharmaceutical dosage forms. Hence, in the present study, a new, sensitive, suitable and robust reversed-phase high performance liquid chromatography method was developed and validated for the determination of Alcaftadine in bulk drug and in dosage form. In RP-HPLC method, Water: Methanol 0.1% OPA. (80:20 %V/V) was used as mobile phase, at a flow rate of 1.0 ml/min, on RP-HPLC system containing UV- detector with Openlab Ezchrom workstation Software with Water Kromasil C18 column (250 mm x 4.6mm ID; 5µm) & column oven temp is 40ºC. The Wavelength was carried out at 282 nm. The method gave suitable retention time i.e. 8 min for Alcaftadine. The results of analysis in the method were validated in terms of Filter study, Solution stability, specificity, Linearity, accuracy and range, precision (Repeatability and intermediate precision), limit of detection, limit of quantification and robustness. A simple and precise method was developed for the assay of Alcaftadine in bulk drug and in Dosage form. The method need regular reagents for doing analysis and also less time consuming, it can be performed routinely in industry for routine analysis of bulk drug and marketed product of Alcaftadine.
Cite this article:
Vidya R. Andhale, Vinayak Gaware. Method Development and Validation of Alcaftadine Drug in Bulk and Dosage Form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(1):26-2 doi: 10.52711/2231-5675.2024.00006
Cite(Electronic):
Vidya R. Andhale, Vinayak Gaware. Method Development and Validation of Alcaftadine Drug in Bulk and Dosage Form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2024; 14(1):26-2 doi: 10.52711/2231-5675.2024.00006 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-14-1-6
REFERENCES:
1. National PBM Drug Monograph. Alcaftadine 0.25% Ophthalmic Solution (Lastacaft). VA Pharmacy Benefits Management Services. Medical Advisory Panel and VISN Pharmacist Executives. 2015
2. US Food and Drug Administration Protecting and Promoting Your Health. 2015
3. (2015) Office of Clinical Pharmacology Review.
4. Church MK, McGill JI. Human ocular mast cells. Curr Opin Allergy Clin Immunol. 2002; 2(5): 419–422.
5. Abelson MB, Udell IJ. H2 -receptors in the human ocular surface. Arch Ophthalmol. 1981; 99(2): 302–304.
6. Chigbu DI. The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye. 2009; 32(1): 3–15. [quiz 43–4].
7. Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov. 2014; 8(2): 139–153.
8. Beckett, A. H., Stenlake, J. B. Practical Pharmaceutical Chemistry, 4th ed.; CBS Publishers and Distributors, India, 2007. [2] Alcaftadine 0.25% ophthalmic solution (Lastacaft) National PBM Drug Monograph http://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Alcaftadine_Drug_Monograph. docx
9. ICH, Q2A, Hamonised Tripartite Guideline, Test on Validation of Analytical Procedures, IFPMA. In: Proceedings of the International Conference on Harmonization, Geneva. March, 1994.
10. ICH, Q2B, Hamonised Tripartite Guideline, Validation of Analytical Procedure: Methodology. IFPMA, In: Proceedings of the International Conference on Harmonization, Geneva. March, 1996.
11. Christian. C. Analytical Chemistry, 6th Edn, 2008; 822-828
12. Ahmad M.Z., Mohammad Ali, Textbook of Pharmaceutical Drug Analysis, 1st Edn. 2009. 2287
13. Parimoo P., Pharmaceutical Analysis. 2005:365-370
14. Connors. K.A. A textbook of Pharmaceutical Analysis, John Wiley and sons, 3rd ed. 1999: 277-288
15. Kasture A.V., Wadodkar S.G., Mahadik K.R., More H.N., Pharmaceutical Analysis: Instrumental methods II, 11th Edn, 2004
16. Gurdeep R, Chatwal S, Anand K. Instrumental methods of chemical analysis. Himalaya Publishing House. 2016
17. Willard HH, Merritt Jr LL, Dean JA, Settle Jr FA. Instrumental methods of analysis 7th Edn. 1995: 1-3
18. Mendham J, Denney R.C., Barnes J.D., M. Thomas, Vogel’s, Textbook of Quantitative Analysis. Pearson Education, Singapore. 2008: 387
19. Jack V Greiner 1, Kimberly Edwards-Swanson, Avner Ingerman - Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%.
20. Mishra PR, Satone D2 and Meshram DB. Development and Validation of HPLC Method for the Determination of Alcaftadine in Bulk Drug and its Ophthalmic Solution. 2016.
21. DeGaulle I Chigbu and Alissa M Coyne- Update and clinical utility of Alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.
22. Jaime Hornecker et al., to evaluate the safety and efficacy of Alcaftadine for the prevention of itching associated with allergic conjunctivitis. One trial compared Alcaftadine to placebo, and another trial compared Alcaftadine to placebo and olopatadine HCl to placebo. 2019.
23. Arya T. Soudi et,al., Stability indicating methods are essential to determine the stability of newly developed dosage forms. 2020.
24. M S Smitha Gowda1, Kiran Kumar L et, al., Comparison of efficacy of topical Alcaftadine (0.25%) versus olopatadine (0.1%) in allergic conjunctivitis. 2021.